Skip to main content

Coronavirus (COVID-19): Latest Updates | Visitation PoliciesVisitation PoliciesVisitation PoliciesVisitation PoliciesVisitation Policies | COVID-19 Testing | Vaccine InformationVaccine InformationVaccine Information

Explore URMC
menu

Emily Dicesare, D.O.

Contact Information

Phone Numbers

Appointment: (585) 341-6880

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentNot Accepting New Patients

Locations

University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 655
Rochester, NY 14642

Faculty Appointments

Patient Care Settings

Emergency Medicine, Hospital Medicine

Biography

Professional Background

Dr. DiCesare is an assistant professor of Emergency Medicine. She obtained her undergraduate degree from Elmira College in 2002, and her Masters in Molecular Biology from New York University in 2005. She received her medical degree from Lake Erie College of Osteopathic Medicine in 2009. Dr. DiCesare completed her residency at the University of Rochester in 2012, and served as Chief Resident from 2011-2012.

Credentials

Specialties

    Education

    2009
    DO | Lake Erie College of Osteopathic Medicine

    Post-doctoral Training & Residency

    06/24/2009 - 08/13/2012
    Residency in Emergency Medicine at University of Rochester Medical Center

    06/20/2009 - 06/23/2010
    Internship in Emergency Medicine at University of Rochester Medical Center

    Publications

    Journal Articles

    5/1/2006
    O'Connor OA, Smith EA, Toner LE, Teruya-Feldstein J, Frankel S, Rolfe M, Wei X, Liu S, Marcucci G, Chan KK, Chanan-Khan A. "The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide." Clinical cancer research : an official journal of the American Association for Cancer Research.. 2006 May 1; 12(9):2902-11.

    2006
    O'Connor, O.A.; Toner, L.; Smith, E.; Vrhoec, R.;. "Sequencing of The Novel antifolate 10-propargyl-10-deaxaaminopterin (PDX) and Gemcitabine induces apoptosis and is markedly superior to Methotrexate (MTX) and cytarabine in murine xenograft models of human aggressive non-Hodgkin's lymphoma." Clinical Cancer Research. 2006; 12: 924-932.

    VIEW ALL PUBLICATIONS